Publications by authors named "Anastasia Iatrou"
Subset #201 is a clinically indolent subgroup of patients with chronic lymphocytic leukemia defined by the expression of stereotyped, mutated IGHV4-34/IGLV1-44 BCR Ig. Subset #201 is characterized by recurrent somatic hypermutations (SHMs) that frequently lead to the creation and/or disruption of N-glycosylation sites within the Ig H and L chain variable domains. To understand the relevance of this observation, using next-generation sequencing, we studied how SHM shapes the subclonal architecture of the BCR Ig repertoire in subset #201, particularly focusing on changes in N-glycosylation sites.
View Article and Find Full Text PDFThe term monoclonal B-cell lymphocytosis (MBL) describes the presence of a clonal B cell population with a count of less than 5 × 10/L and no symptoms or signs of disease. Based on the B cell count, MBL is further classified into 2 distinct subtypes: 'low-count' and 'high-count' MBL. High-count MBL shares a series of biological and clinical features with chronic lymphocytic leukemia (CLL), at least of the indolent type, and evolves to CLL requiring treatment at a rate of 1-2% per year, whereas 'low-count' MBL seems to be distinct, likely representing an immunological rather than a pre-malignant condition.
View Article and Find Full Text PDFVaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients.
Clin Infect Dis
December 2021
Article Synopsis
- The SARS-CoV-2 pandemic has highlighted the urgent need for effective COVID-19 therapies, leading researchers to explore T-cell immunity in diverse groups, including unexposed donors, infected individuals, and vaccinated individuals.
- The study found a direct link between T-cell response strength and patient outcomes, indicating that weak T-cell responses in hospitalized patients correlated with a higher risk of severe outcomes, while strong responses could be produced from recovered and vaccinated donors.
- The findings suggest potential for developing T-cell therapies, emphasizing the importance of robust T-cell immunity in managing COVID-19, while also noting the limitations of T-cell responses in critical patients and those exposed to other coronaviruses.